Ravikanth Papani, MD
Pulmonary Disease · Houston, TXNPI 1861771370
Payments from drug & device makers
Across 92 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$388
- Inspire Medical Systems, Inc.$309
- GSK$240
- Gilead$215
- Actelion Pharmaceuticals US, Inc.$211
- Electromed, Inc.$128
- plus $739 from 19 others
What the payments were for
- Food & beverage$2,11795%
- Education$1125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $388 |
| Inspire Medical Systems, Inc. | 5 | $309 |
| GSK | 8 | $240 |
| Gilead | 12 | $215 |
| Actelion Pharmaceuticals US, Inc. | 8 | $211 |
| Electromed, Inc. | 9 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Bayer | 3 | $71 |
| ZOLL Respicardia, Inc. | 2 | $68 |
| Sanofi | 2 | $63 |
| Boehringer Ingelheim | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Mylan Specialty L.p. | 2 | $43 |
| Amgen | 2 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,229 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 447 | $369,765 |
| OfevNintedanib Esylate | 28 | $364,781 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $21,570 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 94 | $15,301 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $11,070 |
| Wixela InhubFluticasone Propion/Salmeterol | 61 | $10,768 |
| Varenicline Tartrate | 42 | $9,273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 290 | $8,925 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $5,507 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $3,641 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,786 |
| Montelukast Sodium | 42 | $461 |
| Fluticasone Propionate | 15 | $244 |
| Azithromycin | 36 | $145 |
| Levocetirizine Dihydrochloride | 12 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $240 | $402,405519 claims |
| Boehringer IngelheimOfev | $60 | $364,78128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.